MICROSHUNT

MicroShunt features an 8.5-mm SIBS tube with an outer diameter of 350 μm and a 70-μm diameter lumen. It includes multipurpose planar fixation fins to seal the device in order to prevent leakage and migration.^1,2

70-μm diameter was found to prevent chronic hypotony (deation of eye) and prevent clogging.²

Preclinical studies were performed in rabbit eyes to evaluate the biocompatibility and safety of SIBS as compared to silicone controls. The effect of different lumen sizes on IOP was alsostudied.³ 

Demonstrated biostability with a lack of biodegradation byproducts resulted in reduced inammation and minimal scar tissue formation.³

• Demonstrated reduced collagen deposition in the SIBS group compared with the silicone group, with no statistically signicant difference in IOP reduction 7 days after the operation³
• Cells responsible for scarring, known as myobroblasts, were not observed in tissue surrounding the SIBS implants but were observed with the silicone implants³

MicroShunt is the first minimally-invasive glaucoma device to undergo a head-to-head comparative trial versus trabeculectomy in the US and Europe. Theprospective, randomized, controlled, multicenter trial includes 527 patients who are being evaluated to determine efficacy and safety in primary open-angle glaucoma where the IOP is not controlled when using maximally tolerated glaucoma medications.